Eckert & Ziegler Strahlen- und Medizintechnik AG

Earnings Release • Mar 28, 2013

News Details

Corporate | 28 March 2013 07:45

Eckert & Ziegler Fiscal Year 2012: Sales increased.

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Final
Results

28.03.2013 / 07:45

---

Berlin, March 28, 2013. The Berlin company Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope
applications in medicine, science and industry, increased its sales to some
extent in the last business year of 2012. Consolidated sales rose EUR 3.8
million by 3% to EUR 120.0 million (previous year: EUR 116.2 million).

Broken down by the individual segments, turnover was distributed as
follows: The Isotope Products segment, benefiting in particular from the
USD/EUR exchange rate trend, grew by 3% to EUR 56.1 million. In the
Radiation Therapy segment the continuing growth in cancer radiation
equipment contributed to a rise in sales by 4% to EUR 31.8 million. The
Radiopharma segment showed only a slight rise of 1% to EUR 26.0 million.
The Environmental Services segment was able to increase by 12% to EUR 6.2
million thanks to a new large order.

The earnings key figures developed as follows: the EBITDA dropped to EUR
27.5 million (previous year: EUR 30.4 million) and the EBIT was reduced to
EUR 19.7 million (previous year: EUR 22.9 million). The reasons for this
were disproportionately high costs in the area of production (in part in
the Environmental Services segment due to price-related appropriation to
reserves as well as one-time expenditures in conjunction with the
development of a new disposal method and the fulfillment of increased
demands by the authorities) as well as in administrative costs (in part in
the Isotope Products segment due to currency exchange effects as well as
one-time expenditures for a large yet ultimately abandoned acquisition
project). Because of lowered taxes (last year the Radiation Therapy segment
received an adjustment for the inclusion of active deferred taxes) the
income after taxes and minority interests almost equaled that of the
previous year (EUR 10.4 million) with EUR 10.3 million. This corresponds to
earnings per share of EUR 1.95 (previous year: EUR 1.98). The net
liquidity, or the surplus of the means of payment above the loan debts,
grew by 8% to EUR 15.4 million (previous year: EUR 14.3 million).

Altogether, for the coming business years 2013 and 2014 sales of approx.
EUR 125 million or at least EUR 130 million are anticipated. These sales
objectives depict the basic scenario without acquisitions. The Executive
Board continues to see a realistic opportunity for higher sales marks
through strategic company acquisitions. The income after taxes and minority
interests should be approximately EUR 12 million in the year 2013 and over
EUR 15 million in 2014.

The full version of the annual report can be accessed at:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/deut
sch/euzj12e.pdf

The Executive Board and the Supervisory Board will recommend a dividend of
EUR 0.60 per dividend-entitled share (previous year: EUR 0.60) at the
Annual General Meeting on May 17, 2013.

With some 610 employees, the Eckert & Ziegler Group is one of the world's
largest providers of isotope-technical components for radiation therapy and
nuclear medicine.

If you have any questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

End of Corporate News

---

28.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München

End of News DGAP News-Service

205448 28.03.2013